Form 4: Lexicon Pharmaceuticals Director Samuel Barker Reports Stock Transactions
SEC Form 4 Filing
Director Samuel Barker reports acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on April 28, 2024.
Summary
- On April 28, 2024, Samuel L. Barker, a director of Lexicon Pharmaceuticals, reported transactions involving the company's common stock and restricted stock units.
- Barker acquired 8,032 shares of common stock.
- Barker also disposed of 8,032 shares of common stock.
- Following these transactions, Barker beneficially owns 87,649 shares of Lexicon Pharmaceuticals.
- The restricted stock units vest 100% on the first anniversary of the grant date and each unit represents one share of common stock.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing detailing stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 04/28/2024 | Date of transaction involving common stock and restricted stock units. |
| 04/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.